Intensity Therapeutics, Inc. Common stock (INTS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.17M
Last updated: Nov 17, 2026 at 11:04 AM ET
Intensity Therapeutics, Inc. Common stock (INTS) Stock Forecast
Analysts expect Intensity Therapeutics, Inc. Common stock (INTS) to earn -$4.20 per share in the fiscal year ending Dec 31, 2026. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 6 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$4.20
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.21
- EPS consensus
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$4.20 | -$4.25 to -$4.15 | 3 |
| Dec 31, 2027 | -$2.21 | -$3.06 to -$0.92 | 3 |
Quarterly Estimates
The EPS consensus rises from -$0.77 for the quarter ending Dec 31, 2026 to -$0.51 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.77 | -$1.09 to -$0.21 | 7 |
| Mar 31, 2027 | -$0.51 | -$0.81 to -$0.21 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.13.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.20 | -$3.36 | -$3.36 | -$3.36 | -$3.13 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.21 | -$1.99 | -$1.99 | -$1.99 | -$2.70 | N/A |
| Quarter ending Mar 31, 2027 | -$0.51 | -$0.51 | -$0.51 | -$0.51 | N/A | N/A |
Frequently Asked Questions About INTS
What is the INTS stock forecast?
Consensus analyst estimates put Intensity Therapeutics, Inc. Common stock's EPS at -$4.20 for the fiscal year ending Dec 31, 2026. The consensus rating from 6 analysts is Buy.
How do analysts rate INTS stock?
Of 6 analysts covering Intensity Therapeutics, Inc. Common stock, 0 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from INTS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.20, with estimates from -$4.25 to -$4.15 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.21, with estimates from -$3.06 to -$0.92 from 3 analysts.
How many analysts cover INTS?
6 analysts rate Intensity Therapeutics, Inc. Common stock stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
INTS pages: Overview, Earnings, Forecast, Financials, Competitors